Key result
In cultured myotubes and mice, tomatidine stimulated mTORC1 signaling, reduced skeletal muscle atrophy, stimulated hypertrophy, and increased strength and exercise capacity.
Why the study?
Does tomatidine reduce skeletal muscle atrophy in cultured myotubes and mouse models?
Does tomatidine reduce skeletal muscle atrophy in cultured myotubes and mouse models?
Tomatidine is identified as a novel small molecule inhibitor of skeletal muscle atrophy with potential therapeutic utility.
Should not change clinical practice; leaves open tomatidine's therapeutic role pending human trials.
Skeletal muscle atrophy is a common and debilitating condition that lacks an effective therapy. To address this problem, we used a systems-based discovery strategy to search for a small molecule whose mRNA expression signature negatively correlates to mRNA expression signatures of human skeletal muscle atrophy. This strategy identified a natural small molecule from tomato plants, tomatidine. Using cultured skeletal myotubes from both humans and mice, we found that tomatidine stimulated mTORC1 signaling and anabolism, leading to accumulation of protein and mitochondria, and ultimately, cell growth. Furthermore, in mice, tomatidine increased skeletal muscle mTORC1 signaling, reduced skeletal muscle atrophy, enhanced recovery from skeletal muscle atrophy, stimulated skeletal muscle hypertrophy, and increased strength and exercise capacity. Collectively, these results identify tomatidine as a novel small molecule inhibitor of muscle atrophy. Tomatidine may have utility as a therapeutic agent or lead compound for skeletal muscle atrophy. Skeletal muscle atrophy is a common and debilitating condition that lacks an effective therapy. To address this problem, we used a systems-based discovery strategy to search for a small molecule whose mRNA expression signature negatively correlates to mRNA expression signatures of human skeletal muscle atrophy. This strategy identified a natural small molecule from tomato plants, tomatidine. Using cultured skeletal myotubes from both humans and mice, we found that tomatidine stimulated mTORC1 signaling and anabolism, leading to accumulation of protein and mitochondria, and ultimately, cell growth. Furthermore, in mice, tomatidine increased skeletal muscle mTORC1 signaling, reduced skeletal muscle atrophy, enhanced recovery from skeletal muscle atrophy, stimulated skeletal muscle hypertrophy, and increased strength and exercise capacity. Collectively, these results identify tomatidine as a novel small molecule inhibitor of muscle atrophy. Tomatidine may have utility as a therapeutic agent or lead compound for skeletal muscle atrophy.
No takes yet. Share an insight, caveat, or question.
Dyle et al. (2014) studied Skeletal muscle atrophy. Tomatidine was evaluated on mTORC1 signaling, skeletal muscle atrophy, hypertrophy, strength, and exercise capacity. In cultured myotubes and mice, tomatidine stimulated mTORC1 signaling, reduced skeletal muscle atrophy, stimulated hypertrophy, and increased strength and exercise capacity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: